What is the first-line treatment for a 13-year-old female with Crohn disease presenting with chronic diarrhea and altered bowel habits for 3–4 months and colonoscopic findings of transmural inflammation?

First-Line Treatment: Exclusive Enteral Nutrition (EEN)

For this 13-year-old female with newly diagnosed Crohn's disease presenting with chronic diarrhea and transmural inflammation on colonoscopy, exclusive enteral nutrition (EEN) is the recommended first-line treatment (Answer D). 1

Rationale Based on Guidelines

The ECCO/ESPGHAN 2014 consensus guidelines explicitly state that EEN is recommended as first-line therapy to induce remission in children with active luminal Crohn's disease with 96% agreement among experts 1. This recommendation carries the highest level of evidence (EL1) for pediatric populations.

Why EEN Over Other Options:

EEN should be preferred over corticosteroids because it:

• Promotes mucosal healing (74% vs 33% with corticosteroids) 1
• Restores bone mineral density
• Improves growth—critical in a 13-year-old adolescent
• Achieves remission rates of approximately 73-80% 1
• Avoids corticosteroid-related growth suppression and other adverse effects

Treatment Protocol:

• Duration: 6-8 weeks of exclusive liquid formula 1
• Formula type: Oral polymeric (whole protein) formula is preferred—equally effective as elemental formulas but better tolerated and more cost-effective 1
• Delivery: Oral administration first; nasogastric tube only if inadequate oral intake (approximately 120% of daily caloric needs) 1
• Response assessment: If no clinical response within 2 weeks, consider alternative treatment 1

Why Not the Other Options:

A. Systemic Steroids

While corticosteroids are effective (remission rates 57-79%), they are recommended only if EEN is not an option 1. The Canadian guidelines from 2019 support this hierarchy 2. Steroids compromise growth and bone health—particularly problematic in a 13-year-old during critical developmental years.

B. Infliximab

Anti-TNF therapy like infliximab is reserved for:

• Significant fistulizing/perianal disease
• Severe growth retardation in Tanner stages 2-3
• Presence of poor prognostic factors (deep ulcerations, extensive disease)
• Failure of first-line therapy 1

This patient has none of these high-risk features at presentation, making biologics premature as first-line therapy.

C. Methotrexate

Methotrexate is used for maintenance therapy or when thiopurines fail 1. It has a slow onset of action (2-3 months) and is not appropriate for induction therapy in newly diagnosed patients. The Canadian guidelines explicitly recommend against thiopurine monotherapy for induction 2.

Clinical Pearls:

• Transmural inflammation on colonoscopy confirms Crohn's disease but doesn't automatically necessitate biologics
• The 3-4 month symptom duration suggests moderate disease without emergency features
• At age 13, preserving growth potential is paramount—EEN accomplishes this while steroids compromise it
• Food reintroduction after EEN should be gradual over 2-3 weeks with concomitant formula tapering 1

When to Escalate:

Consider moving to corticosteroids or anti-TNF therapy if:

• No response to EEN within 2 weeks 1
• Patient unable/unwilling to comply with exclusive liquid diet
• Presence of high-risk features: deep colonic ulcerations, extensive pan-enteric disease, severe growth retardation (height Z-score < -2.5), or perianal disease 1

The evidence consistently prioritizes EEN for newly diagnosed pediatric Crohn's disease to optimize both disease control and developmental outcomes, making it the clear first choice for this patient.